Overview

Study to Evaluate Safety, Tolerability, and Optimal Dose of Candidate GBM Vaccine VBI-1901 in Recurrent GBM Subjects

Status:
Active, not recruiting
Trial end date:
2025-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety and tolerability of VBI-1901 in subjects with recurrent malignant gliomas (glioblastoma, or GBM).
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
VBI Vaccines Inc.
Treatments:
Carmustine
Lomustine